Table 1.
Overview about demographic data and transplantation history. Data are presented for the whole study population (row 2) and according to the appearance of rejection within the first year after HTx (rows 3 and 4).
| Whole population | Patients without rejection in the first year after HTx | Patients with rejection within the first 3 months after HTx | |
|---|---|---|---|
| n | 46 | 37 | 6 |
| Age at HTx (±SD) | 50.6 ± 12.5 yrs | 50.5 ± 12.8 yrs | 48.3 ± 11.3 yrs |
| Female gender (%) | n = 13 (28%) | n = 13 (35%) | n = 1 (17%) |
| Disease leading to HTx | |||
| DCM | n = 23 | n = 20 | n = 3 |
| ICM | n = 16 | n = 12 | n = 2 |
| Other | n = 6 | n = 5 | n = 1 |
| Assist device support before HTx | n = 5 | n = 4 | n = 1 |
| Re-HTx | n = 1 | n = 0 | n = 1 |
| Death within the first year after HTx | n = 2 | n = 2 | n = 0 |
| Panel reactive antigen before HTx | |||
| PRA = 0 | n = 40 | n = 33 | n = 5 |
| PRA > 0, <20 | n = 3 | n = 1 | n = 1 |
| PRA ≥ 20 | n = 2 | n = 2 | n = 0 |
| Transplant rejection (histopathological EMB grade ≤ grade IB or higher) | |||
| 1st quarter | n = 6 | — | 6 |
| 2nd quarter | n = 1 | — | — |
| 2nd half year | n = 2 | — | — |
DCM, dilated cardiomyopathy; EMB, endomyocardial biopsy; HTx, heart transplantation; ICM, ischemic cardiomyopathy; PRA, panel reactive antibody; Re-HTx, repeat heart transplantation; SD, standard deviation.